Product Description
Benzodepa is an aziridine alkylating agent that cross-links with DNA, causing inhibition of DNA synthesis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Benzodepa)
Mechanisms of Action: DNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Atox Bio
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Peritonitis|Soft Tissue Infections|Fasciitis, Necrotizing|Wound Infection|Acute Kidney Injury|Sepsis|Fournier Gangrene|Communicable Diseases
Phase 2: Communicable Diseases|Soft Tissue Infections|Acute Kidney Injury|Sepsis
Phase 1: Hypertension|Shock, Septic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01166984 |
ATB-001 | P1 |
Completed |
Hypertension|Shock, Septic |
2011-06-01 |
2021-04-28 |
Primary Endpoints|Treatments |
|
2018-002547-29 |
REAKT | P2 |
Completed |
Acute Kidney Injury|Sepsis |
2019-10-21 |
2022-03-13 |
Treatments |
|
NCT01417780 |
ATB-201 | P2 |
Completed |
Communicable Diseases|Soft Tissue Infections |
2012-09-01 |
2021-08-19 |
Primary Endpoints |
|
NCT03403751 |
SA-AKI | P3 |
Terminated |
Peritonitis|Wound Infection|Acute Kidney Injury|Soft Tissue Infections|Sepsis |
2019-12-14 |
2021-09-17 |
||
2018-001125-15 |
ACCUTE | P3 |
Completed |
Soft Tissue Infections |
2019-10-18 |
2022-03-13 |
Treatments |
|
NCT02469857 |
ACCUTE | P3 |
Completed |
Fasciitis, Necrotizing|Soft Tissue Infections|Fournier Gangrene|Communicable Diseases |
2019-08-18 |
2021-01-29 |
Primary Completion Date|Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/18/2019 |
News Article |
Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI |
|
06/18/2019 |
News Article |
Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI |
|
02/14/2019 |
News Article |
Atox Bio Announces Appointment of Robert Greif as Chief Commercial Officer |